This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hlatky, M. A. Search for Related Content PubMed PubMed Citation Articles by Hlatky, M. A. Related Collections Health policy and outcome research Congestive Related Article

(Circulation. 2004;110:644-645.)
© 2004 American Heart Association, Inc.

Editorial

Underuse of Evidence-Based Therapies

Mark A. Hlatky, MD

From the Donald W. Reynolds Cardiovascular Clinical Research Center, Stanford University School of Medicine, Stanford, Calif.

Correspondence to Mark A. Hlatky, MD, Stanford University School of Medicine, HRP Redwood Building, Room 150, Stanford, CA 94305- 5405. E-mail hlatky@stanford.edu

Key Words: Editorials • evidence-based medicine • quality indicators • angiotensin-converting enzyme inhibitors

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Cardiovascular specialists have been leaders in medicine because of our willingness to study major clinical issues by means of randomized clinical trials. Consequently, the evidence supporting many cardiovascular treatments is substantial, especially when the results of multiple large clinical trials are consistent in showing strong benefits. Cardiovascular professional societies also have been at the forefront in forging consensus among clinical experts and codifying best practice into practice guidelines. It is reasonable to expect that a treatment demonstrated to be effective in clinical trials and strongly endorsed by professional guidelines will be adopted by practicing physicians and consistently used in day-to-day patient care.

See p 724

Angiotensin-converting enzyme (ACE) inhibitors have followed this pathway of building evidence and professional consensus. Many randomized clinical trials have clearly shown that ACE inhibitors reduce mortality and morbidity rates among patients with heart failure and left ventricular systolic dysfunction. Pooled data from 5 large trials¹ showed the odds of death of patients randomized to ACE inhibitors were reduced by 26% compared with placebo, translating into roughly 6 fewer deaths per 100 patients treated. The economic outcomes also are favorable because much of the cost of prescribing ACE inhibitors for heart failure is recouped by the reduced need for hospital admissions. Consequently, the use of ACE inhibitors for heart failure is quite cost-effective.² The American College of Cardiology/American Heart Association Guidelines Committee has weighed the evidence and given ACE inhibitors for treatment of heart failure a Class I recommendation.³ Indeed, use of ACE inhibitors is so . . . [Full Text of this Article]

Related Article:

National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction

Frederick A. Masoudi, Saif S. Rathore, Yongfei Wang, Edward P. Havranek, Jeptha P. Curtis, JoAnne Micale Foody, and Harlan M. Krumholz
Circulation 2004 110: 724-731. [Abstract] [Full Text]

This article has been cited by other articles:

				J.-P. Bassand, S. Priori, and M. Tendera Evidence-based vs. 'impressionist' medicine: how best to implement guidelines Eur. Heart J., June 2, 2005; 26(12): 1155 - 1158. [Abstract] [Full Text] [PDF]

				T. Sabatini, R. Rozzini, M. Trabucchi, F. A. Masoudi, E. P. Havranek, S. S. Rathore, Y. Wang, J. P. Curtis, J. M. Foody, and H. M. Krumholz Letter Regarding Article by Masoudi et al, "National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction" * Response Circulation, May 3, 2005; 111(17): e276 - e277. [Full Text] [PDF]